U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
Vor Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vor Bio Reports First Quarter 2023 Financial Results And Provides Company Update
Vor Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Vor Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Vor Biopharma Reports Fourth Quarter Results
Vor Biopharma Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Vor Biopharma Inc Files Prospectus Related To Proposed Sale Of Common Stock From Time To Time For Offering Price Of $125 Million By Selling Stockholder
Brief: Vor Biopharma Inc Files Prospectus Relates To Proposed Resale From Time To Time Of Up To 11.6 Million Shares Of Common Stock By Selling Stockholder
Brief: Vor Biopharma Says On Dec 9, 2022, Co Notified Jefferies LLC Of Its Decision To Terminate The Open Market Sale Agreementsm, Dated As Of March 14, 2022
Brief: Vor Biopharma Inc - Offering 15.3 Million Shares Of Common Stock At A Purchase Price Of $4.30 Per Share - Filing
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Solaredge Technologies
Vor Bio soars as initial data from blood cancer study shows promise
U.S. STOCKS ON THE MOVE-Uniti Group, Pfizer, Moleculin Biotech
U.S. STOCKS ON THE MOVE-Prometheus, Pinterest, Roivant
Vor Bio up as initial data from blood cancer study shows promise
Brief: First AML Patient Successfully Transplanted With Vor Bio’S Investigational Trem-Cel (VOR33) And Tolerated Mylotarg
Vor Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Vor Bio Reports Third Quarter 2022 Financial Results